Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,883
Employees75,883
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,883
Employees75,883

NVS Key Statistics

Market cap
274.98B
Market cap274.98B
Price-Earnings ratio
18.47
Price-Earnings ratio18.47
Dividend yield
2.55%
Dividend yield2.55%
Average volume
1.05M
Average volume1.05M
High today
$130.45
High today$130.45
Low today
$129.15
Low today$129.15
Open price
$129.81
Open price$129.81
Volume
1.34M
Volume1.34M
52 Week high
$130.45
52 Week high$130.45
52 Week low
$96.06
52 Week low$96.06

NVS News

TipRanks 2d
Novartis AG: Balancing Promising Pipeline Developments with Valuation and Risk Concerns

Bank of America Securities analyst Sachin Jain reiterated a Hold rating on Novartis AG today and set a price target of CHF111.00. Elevate Your Investing Strateg...

TipRanks 2d
Novartis Stock Beats Harder on $5.2B Chinese Heart Disease Deal

Shares in Swiss drugmaking giant Novartis (NVS) were looking perkier today after it sealed a $5.2 billion deal with a Chinese peer fighting heart disease. Eleva...

TipRanks 2d
Arrowhead Stock Soars over $200M Deal with Swiss Pharma Giant Norvatis

Arrowhead’s (ARWR) stock jumped over 16% higher on Tuesday to $25.68 after the American biopharma company announced a deal with Switzerland-based pharmaceutical...

Analyst ratings

64%

of 25 ratings
Buy
20%
Hold
64%
Sell
16%

More NVS News

Seeking Alpha 3d
Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has entered into a global partnership with Novartis (NYSE:NVS), for the development of ARO-SNCA, the company's siRNA the...

Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy
TipRanks 6d
Novartis’ Leqvio shows statistically significant LDL-C goal achievement in study

Novartis (NVS) announced “positive” results from V-DIFFERENCE, a Phase IV study evaluating Leqvio compared to placebo, both administered on top of individually...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.